European Hematology Association

Servier Targets Transformative Treatment of Cancer at ASCO 2023

Retrieved on: 
星期四, 五月 25, 2023
Glioma, Bevacizumab, Capecitabine, INDIGO, Central European Summer Time, European Hematology Association, Survival, American Society of Clinical Oncology, Research, Acute myeloid leukemia, ASCO, MDS, AML, Azacitidine, Patient, Trifluridine/tipiracil, Cancer, EHA, IDH, IDH1, Chondrosarcoma, Safety, Society, European Commission, Cholangiocarcinoma, Dietary supplement, Nursing, Pharmaceutical industry, Laboratoires Servier

BOSTON and PARIS, May 25, 2023 /PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, will showcase new data across its robust oncology portfolio at the American Society of Clinical Oncology (ASCO) annual meeting June 2-6, 2023. These latest data, including a plenary session selection, underscore the breadth of Servier's oncology pipeline and portfolio and the company's commitment to improving outcomes for difficult and hard-to-treat cancers with high unmet medical needs.

Key Points: 
  • These latest data, including a plenary session selection, underscore the breadth of Servier's oncology pipeline and portfolio and the company's commitment to improving outcomes for difficult and hard-to-treat cancers with high unmet medical needs.
  • Among the data to be presented is a late breaking abstract featuring the results from the Phase 3 INDIGO study of vorasidenib in patients with residual or recurrent grade 2 IDH-mutant glioma.
  • "Servier is leading the scientific research with IDH inhibition across a variety of difficult to treat cancers, and this year at ASCO, we are excited to showcase data that has the potential to shift the treatment paradigm for patients with IDH-mutant glioma," said Susan Pandya, M.D., Head of Cancer Metabolism Global Development Oncology & Immuno-Oncology, Servier.
  • Servier abstracts being presented at EHA are listed below (all times in Central European Summer Time) and are available online on the EHA website here .

Alpine Immune Sciences to Present Data from RUBY-1, a Phase 1 Study of Povetacicept, at Upcoming Scientific Congresses

Retrieved on: 
星期五, 五月 19, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Volunteering, European Hematology Association, APS, Lupus, SLE, European Congress of Radiology, Festhalle, Autoimmunity, Toronto Congress Centre, ALPN, EHA, EULAR, Treatment, Inflammation, Pharmaceutical industry, Vaccine, Tolerability, Safety, Pharmacokinetics

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company will present data from RUBY-1, a phase 1 study of povetacicept in healthy adult volunteers, at multiple upcoming scientific congresses, including participation in a poster tour at the European Congress of Rheumatology (EULAR) and an oral presentation at the European Hematology Association (EHA).

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company will present data from RUBY-1, a phase 1 study of povetacicept in healthy adult volunteers, at multiple upcoming scientific congresses, including participation in a poster tour at the European Congress of Rheumatology (EULAR) and an oral presentation at the European Hematology Association (EHA).
  • Presentation Title: A Placebo-Controlled Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Povetacicept, a Potent Dual BAFF/APRIL Antagonist, for the Treatment of Systemic Lupus Erythematosus
    Session Name: Short Oral Presentation Session 16, SLE Treatment 2
    Poster Title: A Placebo-Controlled Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Povetacicept (ALPN-303), a Potent Dual BAFF/APRIL Antagonist, for the Treatment of Systemic Lupus Erythematosus and Other B Cell-Related Disorders (RUBY-1)
    Session Name: A novel journey into SLE, Sjögren's and APS
    Poster Title: Povetacicept (ALPN-303), A Potent Dual BAFF/APRIL Antagonist, for the Treatment of Autoimmune Cytopenias and Other Antibody-Related Diseases
    Location: Panorama 2, Congress Centre, Forum, Festhalle and Halls 1 and 3 of Messe Frankfurt, Frankfurt, Germany
    Presentation Title: Phase 1 Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Povetacicept for Autoimmune Glomerulonephritides

Notable Labs to Present Predictive Precision Medicine Platform (PPMP) Data in Juvenile Myelomonocytic Leukemia (JMML) at European Hematology Association (EHA) Hybrid Congress June 8 – 15, 2023

Retrieved on: 
星期三, 五月 17, 2023
European Hematology Association, Tretinoin, Cancer, Patient, Drug combination, Cytarabine, EHA, Pharmaceutical industry, Medical imaging, JMML

FOSTER CITY, Calif., May 17, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Inc. (“Notable”), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today announced an abstract has been accepted for poster presentation at the European Hematology Association (EHA) Hybrid Congress to be held in Frankfurt, Germany on June 8 – 15, 2023.

Key Points: 
  • FOSTER CITY, Calif., May 17, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Inc. (“Notable”), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today announced an abstract has been accepted for poster presentation at the European Hematology Association (EHA) Hybrid Congress to be held in Frankfurt, Germany on June 8 – 15, 2023.
  • The abstract highlights results of a research study demonstrating the utility of Notable’s PPMP for identifying potentially more effective pre-hematopoietic stem cell therapy drug combinations, as compared to regimens currently used in JMML.
  • The study showed that the addition of tretinoin to fludarabine + cytarabine or to 5-azacitidine, or calcitriol to 5-azacitidine, to patients’ samples further reduced the ex vivo blast counts compared to treatment with only fludarabine + cytarabine, or 5-azacitidine, respectively.

X4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Duration of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome

Retrieved on: 
星期二, 五月 16, 2023
Infection, WHIM syndrome, Arm, Therapy, European Hematology Association, WHIM, Federation of Clinical Immunology Societies, CIS, CN, Patient, Immune system, EHA, Rare, FDA, Caregiver, Pharmaceutical industry

Following the announcement of positive top-line data from the 4WHIM trial in November 2022, today’s event focuses on the impact of mavorixafor on the rate, severity, and duration of infections in trial participants.

Key Points: 
  • Following the announcement of positive top-line data from the 4WHIM trial in November 2022, today’s event focuses on the impact of mavorixafor on the rate, severity, and duration of infections in trial participants.
  • “Today, we’re announcing that mavorixafor treatment demonstrated statistically significant and clinically meaningful improvements across a number of key infection metrics versus placebo in our pivotal, Phase 3 trial in those diagnosed with WHIM Syndrome,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals.
  • Approximately 90% of participants in the trial continued on to receive mavorixafor treatment in the ongoing open-label extension study.
  • The X4 live-event webcast presentation and the accompanying slides are now accessible on the investor relations section of the X4 website at www.x4pharma.com .

Ryvu Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
星期二, 五月 16, 2023
SDMA, MTAP, Incentive program, WSE, Congress, EIB, Myeloproliferative neoplasm, Warsaw Stock Exchange, Service, MTA, Culture, Research, WT, Growth, Phase, Conference, Safety, Common, BioNTech, WIG20, 100 Best Companies to Work For, Pancreatic serous cystadenoma, Publication, SWIG, CEE, Therapy, PRMT5, European Hematology Association, Exelixis, Good clinical data management practice, MDS, AML, EHA, Pharmaceutical industry, Vaccine, Cryptocurrency, Patient

These molecules can selectively inhibit the growth of MTAP-deleted cancer cells in prolonged 3D culture, which correlates with the inhibition of PRMT5-dependent protein symmetric dimethylation (SDMA).

Key Points: 
  • These molecules can selectively inhibit the growth of MTAP-deleted cancer cells in prolonged 3D culture, which correlates with the inhibition of PRMT5-dependent protein symmetric dimethylation (SDMA).
  • Ryvu was also the winner in three other categories: “Investor Relations”, “Development Perspectives”, and “Products and Services Innovation”.
  • Initiation of Phase 2 trials of RVU120 in solid tumors and AML/HR-MDS is expected in 2H 2023.
  • As of May 11, 2023, Ryvu Therapeutics held $71.8M in cash, cash equivalents and bonds.

Legend Biotech to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings

Retrieved on: 
星期二, 五月 16, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Abstract, DPD, Multiple myeloma, PVD, Dexamethasone, ASCO, Bortezomib, CAR, European Hematology Association, American Society of Clinical Oncology, Patient, EHA, Annual general meeting, Poster, Daratumumab, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Food, BCMA, Pharmaceutical industry

“We are pleased that the latest data from the CARTITUDE-4 study will be officially presented at the meetings.

Key Points: 
  • “We are pleased that the latest data from the CARTITUDE-4 study will be officially presented at the meetings.
  • This was the study that showed — in front of the international community back in 2017 —promising results in heavily pretreated patients with multiple myeloma.
  • CARTITUDE-1 is a Phase 1b/2 study evaluating cilta-cel for the treatment of heavily pretreated patients with relapsed or refractory multiple myeloma.
  • This first-in-human, Phase 1 study evaluates LCAR-B38M CAR-T cells in patients with relapsed and refractory multiple myeloma.

Gracell Biotechnologies Reports First Quarter 2023 Unaudited Financial Results, and Provides Corporate Update

Retrieved on: 
星期一, 五月 15, 2023
Exercise, Persephone Borrow, Indian Institutes of Technology, IIT, KOL, ASH, CD19, European Hematology Association, HLA, Lymphoid leukemia, ADS, Clinical trial, NHL, Cancer, Research, SLE, ASCO, MRD, Congress, Cytokine release syndrome, Patient, Investment, B-ALL, Graceling, SAN, TME, Webcast, Society, ORR, SMART, Conference, BCMA, Pharmaceutical industry, Mobile phone, Vaccine, Medical device, Nursing, Satellite navigation device, Cryptocurrency, Security (finance), Broadcasting, RRMM, IND

We are on track to initiate the U.S. IND trial for GC012F in RRMM in the second quarter of 2023,” said Dr. William (Wei) Cao, founder, Chairman and CEO of Gracell.

Key Points: 
  • We are on track to initiate the U.S. IND trial for GC012F in RRMM in the second quarter of 2023,” said Dr. William (Wei) Cao, founder, Chairman and CEO of Gracell.
  • Company-sponsored Phase 1b/2 clinical trial in U.S. (NCT05850234) evaluating GC012F in RRMM on track to initiate in the second quarter of 2023.
  • Company-sponsored Phase 1/2 clinical trial in China evaluating GC012F in RRMM expected to initiate in the third quarter of 2023.
  • On track to commence a China IIT for GC506 in Claudin18.2-positive solid tumors in the second quarter of 2023.

Disc Medicine Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
星期一, 五月 15, 2023
Diamond, Sodium- and chloride-dependent glycine transporter 1, Interim, Diamond–Blackfan anemia, Ruxolitinib, Chronic kidney disease, European Hematology Association, OrbiMed, AURORA, G&A, Porphyria, Inflammation, MF, Dialysis, Net, Congress, IRON, ATM, Erythropoiesis, Glycine, Development, Patient, Administration, Anemia, EHA, Mab, Research, FDA, Polycythemia, CKD, IND, NIH, TMPRSS6, Safety, Pharmaceutical industry, Generic drug, Vaccine, Cryptocurrency, Nursing, Disc, EPP, Greater China

Interim data will be presented at EHA Congress on June 9, 2023, with an accompanying management call at 7:30 am ET the same day.

Key Points: 
  • Interim data will be presented at EHA Congress on June 9, 2023, with an accompanying management call at 7:30 am ET the same day.
  • Announced a collaboration with NIH to study bitopertin in patients with Diamond-Blackfan Anemia in March 2023; the study is expected to initiate mid-year 2023.
  • First Quarter 2023 Financial Results:
    Cash Position: Cash and cash equivalents were $236.4 million as of March 31, 2023 compared to $194.6 million as of December 31, 2022.
  • Net Loss: The net loss was $22.8 million for the first quarter of 2023, as compared to $9.9 million for the first quarter of 2022.

Innate Pharma to Present IPH6501 Preclinical Data at The EHA 2023 Congress

Retrieved on: 
星期一, 五月 15, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, European Hematology Association, CD16, Cancer, NK, Euronext Paris, IPH, IPHA, NCR1, EHA, Congress, Therapy, Natural killer T cell, Tetra, Vaccine

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that new preclinical data on its IPH6501 tetra-specific ANKET® (Antibody-based Natural Killer cell Engager Therapeutics) have been selected for oral presentation at the European Hematology Association (EHA) 2023 congress, being held 8 to 15 June 2023 in Frankfurt, Germany.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that new preclinical data on its IPH6501 tetra-specific ANKET® (Antibody-based Natural Killer cell Engager Therapeutics) have been selected for oral presentation at the European Hematology Association (EHA) 2023 congress, being held 8 to 15 June 2023 in Frankfurt, Germany.
  • ANKET® is Innate’s proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of cancer.
  • By providing proliferation and activation signals targeted to NK cells, tetra-specific ANKET® leverages the advantages of harnessing NK cell effector functions against cancer cells.
  • IPH6501, the first tetra-specific ANKET®, continues toward a Phase 1 clinical trial in 2023.

Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at EHA

Retrieved on: 
星期五, 五月 12, 2023
University College London, UCL, European Hematology Association, ALL, Safety, Doctor of Philosophy, Acute leukemia, Congress, Royal College of Pathologists, EHA, Therapy, Vaccine, MD

LONDON, May 12, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the abstract for the pivotal Phase 2 FELIX study of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL) has been selected for an oral presentation at the European Hematology Association (EHA) 2023 Congress, being held June 8 - 11, 2023, in Frankfurt.

Key Points: 
  • LONDON, May 12, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the abstract for the pivotal Phase 2 FELIX study of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL) has been selected for an oral presentation at the European Hematology Association (EHA) 2023 Congress, being held June 8 - 11, 2023, in Frankfurt.
  • Safety and efficacy of Obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19CAR in relapsed/refractory adult B-Cell acute lymphoblastic leukemia (r/r B-ALL): Topline results of the pivotal FELIX study
    Presenting Author: Dr. Claire Roddie, MD, PhD, FRCPath, Consultant Haematologist and Honorary Senior Lecturer, Cancer Institute, University College London (UCL)